https://www.selleckchem.com/pr....oducts/valproic-acid
tis (two [3%]); and in group C, neutropenia (four [6%]) and pleural effusion (two [3%]). Two deaths were attributed to treatment one due to pulmonary fibrosis in group B and one due to febrile neutropenia in group C. INTERPRETATION The combination of abemaciclib, fulvestrant, and trastuzumab significantly improved progression-free survival versus standard-of-care chemotherapy plus trastuzumab while showing a tolerable safety profile. Our results suggest that a chemotherapy-free regimen might potentially be an alternative treatment
Like
Comment
Share
